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ABSTRACT 
 
Meredith Grace Mock: Influence of Probiotics on Body Composition and Health in Occupational 
Shift-workers 
(Under the direction of Abbie Smith-Ryan) 
 
 The present study sought to investigate the effects of a multi-strain probiotic (PRO) on body 
composition, regional adiposity, and a series of associated metabolic health outcomes.  Female healthcare 
workers employed on a rotating-shift schedule (n=41) completed baseline anthropometric assessments, a 
fasted blood draw, mood questionnaires, and an exercise fatigue test. Identical post-tests occurred 
following six weeks daily supplementation with (PRO) or placebo (PLA). PRO attenuated fat mass gains 
(Δ0.14; CI: -0.46–0.75kg) compared to PLA (Δ0.79 kg; CI: 0.03–1.54 kg), and resulted in modest 
reductions in visceral adiposity (VAT).  Metabolic biomarkers (total cholesterol, HDL, and glucose) were 
not influenced by either treatment (p>0.05).  Non-significant, yet clinically relevant improvements in 
anxiety and fatigue were observed with PRO, but exercise performance was unaffected.  Results indicate 
a potential protective effect of PRO, and may direct future occupational health investigations of various 
probiotic strains in susceptible populations.    
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CHAPTER I: INTRODUCTION 
Increased mortality and morbidity among the overweight and obese is well documented, with 
individuals exhibiting higher risk of cardiovascular disease, cancer, and other comorbidities of metabolic 
syndrome.1  In addition to metabolic disturbances, there is accumulating evidence linking excess body 
weight and gut dysbiosis, the disruption of ecologic equilibrium in the digestive tract.2  Components of 
the modern “obesogenic environment,” including westernized diet, lack of physical activity, and elevated 
stress levels, may compromise digestive health and further exacerbate obesity risk factors.3  Probiotic 
supplementation has been established as a successful therapy to restore gut homeostasis, reduce infection 
risk, and alleviate inflammatory bowel disease.4  Defined by the World Health Organization as “live 
microorganisms that confer a health benefit on the host,”5 probiotics have recently gained attention as a 
potential weight loss aid.  Furthermore, probiotics have also been reported to especially benefit abdominal 
adiposity, which may serve as an even stronger prognostic of metabolic health risk.6,7  Unlike other 
pharmacological or surgical treatments, probiotics may provide a safer and more economical approach to 
improving body composition and reducing obesity-related symptoms.  
The gastrointestinal (GI) tract is home to trillions of bacteria, with an estimated 500-1000 species 
making up the gut microbial community.8  Having co-evolved with its human hosts, the microbiota is 
integral to host physiology, playing a role in energy metabolism, nutrient synthesis and absorption, as 
well as immune function.9  Though some elements of the human microbiota are universal,10 exceptional 
variability in species and strain population exists, especially between metabolically healthy and unhealthy 
individuals.11,12  A landmark study by Turnbaugh and colleagues10 discovered notable deviations in the 
microbiome (collective bacterial genome) of obese versus lean twins, suggesting environmental factors, 
such as diet and activity, shape the bacterial landscape of the gut.10  Therefore, modulating microbiota 
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composition with probiotics may benefit metabolic health through the following mechanisms of action: 
(1) altered energy harvest; (2) improved immune function; and (3) enhanced intestinal integrity. 
Disrupted energy balance, which occurs when dietary consumption exceeds the amount of energy 
expended or excreted, is often discussed in the context of obesity.  As the primary site of digestion and 
absorption, the human GI tract is highly involved in regulating energy uptake and energy loss in the feces 
and urine.11  Obese-phenotype microbiota tend to contain higher amounts of bacterial strains that possess 
the ability to hydrolyze polysaccharides and fatty acids a host could not otherwise break down, increasing 
the over amount of calories extracted from food.13  Backhed et al.14 demonstrated that germ-free mice 
absorbed significantly fewer monosaccharides in the gut than conventional mice fed a western-style diet. 
Following the introduction of gut bacteria from obese mice, formerly germ-free mice also exhibited 
suppression of fasting induced adipocyte factor (Fiaf), a protein inhibitor of lipases responsible for fat 
deposition. Thus, microbiota modulation via probiotics may increase Fiaf expression and subsequently 
reduce fat storage.14,15  Probiotics have also been shown to improve insulin sensitivity16 and stimulate the 
secretion of satiety hormones,17 benefitting energy metabolism and attenuating overall energy intake.  
The ability of probiotics to bolster host immunity has been well-documented in both human and 
murine models.18  Upon introduction into a host gut, probiotics have been demonstrated to hold a 
competitive advantage over any existing pathogens for adhesion sites and essential nutrients.18,19 
Additionally, certain bacterial strains can produce compounds that have an inhibitory effect on harmful 
microbes, such as Rotavirus and other food-borne pathogens.20  Probiotics may also promote the 
maturation of T and B cells through interactions with dendritic cells located in the GI tract, benefitting the 
adaptive immune system.21  As a primary entry site into the host’s bloodstream, the intestinal tract also 
plays an integral role supporting host’s innate immune defenses.2  The passage of foreign particles across 
the intestinal barrier, colloquially known as “leaky gut syndrome,” adversely affects host health by 
inciting an inflammatory response.22,23  
Associations between gut permeability and obesity, which in itself promotes chronic 
inflammation, suggest a reciprocal interaction that may exacerbate health prognoses.  Furthermore, excess 
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abdominal fat has been especially tied to low-grade systemic inflammation, likely due to the heightened 
secretion of pro-inflammatory cytokines by adipocytes.24  While factors such as poor diet and 
environmental toxins can compromise the gut barrier,4,25 probiotics may help reverse intestinal 
permeability by enhancing tight junction complexes, the membrane proteins responsible for maintaining 
gut epithelium.18,20,23  In a study of 23 endurance-trained males, Lampretch et al.26 reported significant 
reductions in Zonulin, a protein indicating compromised tight junction structure, following 12 weeks of 
probiotic supplementation. Probiotics also benefit gut barrier function by promoting secretion and 
maintenance of the intestinal mucosa, a protective layer of mucus lining the epithelium.20  
Probiotics have also been demonstrated as a promising therapy for disorders often indirectly 
associated with metabolic syndrome, including chronic fatigue, exercise intolerance, anxiety, and 
depression.27,28  The brain’s influence on the gut is highly recognized, considering the well-documented 
co-morbidity between elevated stress levels and gastrointestinal disorders.27,29  Moreover, accumulating 
evidence brings to light the bidirectional interaction between GI bacterial composition and the nervous 
system, deemed the “microbiota-gut-brain axis.”13,29  The immune-inflammatory response associated with 
gut dysbiosis has been correlated with several mood-related symptoms.13  Additionally, different gut 
bacterial strains produce a range of neurotransmitters, the biochemical signals integral to mood and 
cognitive function.29  Bravo and colleagues30 demonstrated increased GABA production in mice 
following a 28-day stint of L. rhamnosis, resulting in reduced anxiety and depressive behaviors in a 
forced swimming task.  Though the majority of psychotherapy interventions have been evaluated in mice, 
a handful of human studies have reported improved mood scores in as little as two weeks of probiotic 
administration.29  
As mentioned earlier, components of the current obesogenic environment include lack of sleep, 
poor diet, and chronic exposure to stress.3  Though much of the Western population is at risk for such 
lifestyle factors, those employed as rotating shift-workers may be even more susceptible.  Fittingly, two 
major characteristics highlighted in Moore-Ede and Richardson’s31 definition of shiftwork maladaptive 
syndrome involve gastrointestinal pathologies and cardiovascular complications.  Furthermore, greater 
 
 
4 
health risk has been observed in female shift-workers, potentially due to non-work family obligations.32 
Nursing is one of the most notable fields utilizing the shiftwork model, with women constituting a large 
majority of all nurses.33  Additionally, alarming rates of metabolic syndrome within the nursing 
profession have gained attention in both research and clinical arenas, considering the integral role of 
nurses in healthcare.34  In a cross-sectional study comparing regular day- and rotating-shift nurses, Zhen 
and associates35 found the incidence of functional bowel disorder, anxiety, and sleep disturbances 
significantly higher in the rotating shift cohort. Probiotic treatment may especially benefit the female 
nursing population, considering probiotic therapies target many overlapping contributors to excess 
adiposity and its comorbidities.  
A significant and complex interrelationship exists between disrupted gut microbiota, excess body 
fat, and the adverse health effects accompanying both. Though much literature points to the potential of 
probiotics to ameliorate metabolic disturbances, human studies evaluating changes in body composition 
are scarce. Furthermore, we are not aware of any intervention that explores effects on fat distribution in 
shift-working females, who may be at greater risk for gut dysbiosis and its implications for metabolic 
health. 
Purpose 
1. The primary purpose of this study was to explore the influence of six weeks probiotic 
supplementation on body composition and regional adiposity in female rotating-shift healthcare 
workers.  
a. Potential effects of probiotics on fat mass, percent body fat, and lean mass were assessed. 
b. Visceral fat distribution and waist-to-hip ratio was determined to assess regional 
adiposity.  
2. A secondary purpose of this study was to assess potential improvements in blood markers of 
metabolic health. 
a. Total cholesterol (TC), high-density lipoproteins (HDL), and glucose (GLU) were 
assessed. 
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3. The tertiary purpose of this study was to determine the influence of probiotic supplementation on 
psychological and physiological fatigue. 
a. Subject-reported mood and rating of fatigue were evaluated using the Hospital Anxiety 
and Depression Survey (HADS) and the Chalder Fatigue Survey (CFQ-11). 
b. Physiological fatigue was determined with an exercise time-to-exhaustion test. 
Research Questions 
1. Does probiotic supplementation alter body composition and regional adiposity in shift-working 
females? 
2. Does probiotic supplementation improve profiles of metabolic biomarkers?  
3. Does probiotic supplementation improve feelings of psychological or physiological fatigue? 
Research Hypotheses  
1. Chronic probiotic supplementation would favorably alter body composition and regional 
adiposity. 
2. Chronic probiotic supplementation would improve profiles of metabolic biomarkers. 
3. Chronic probiotic supplementation would improve psychological or physiological fatigue 
following six weeks of daily probiotic ingestion.  
a. Probiotics would benefit mood and perceived fatigue. 
b. Exercise time-to-exhaustion would be improved following probiotic supplementation. 
Delimitations 
1. Participants were premenopausal females employed as night or rotating day/night shift healthcare 
staff, ages 21-55 years.  
2. The study consisted of three laboratory visits. 
3. The duration of supplementation was six weeks. 
4. Regional fat distribution and body composition was analyzed using dual-energy x-ray 
absorptiometry (DEXA), bioelectrical impedence spectroscopy (BIS), and ultrasound (US).  
5. Exercise time-to-exhaustion was evaluated using a treadmill time-to-exhaustion test.  
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6. The Hospital Anxiety and Depression Survey (HADS) and Chalder Fatigue Survey (CFQ-11) was 
utilized to assess subject mood and fatigue.  
7. Participants had not taken a probiotic supplement for at least two months prior to the study. 
8. Participants were excluded from the study if dietary analysis indicated frequent consumption of 
probiotic-containing functional foods. 
9. Participants were excluded if she had lost or gained  >3 kg within the previous two months. 
Limitations 
1. Subject recruitment took place throughout healthcare facilities in the Raleigh-Durham region, 
including the University of North Carolina at Chapel Hill Hospital, UNC REX Hospital, Duke 
University Hospital, Durham VA Hospital, and Duke Regional Hospital. Therefore, subject 
selection was not truly random. 
2. Quantity and variety of probiotic strains was not measured post-ingestion, meaning the viability 
of probiotics in the intestinal tract was not evaluated.  
3. Though dietary intake was recorded and accounted for, diet changes may still have affected 
individual body composition beyond the experimental intervention.  
4. This probiotic intervention utilized the same strains for all subjects, so the level of efficacy may 
vary based on individual preexisting gut health. 
Assumptions 
Theoretical 
1. Subjects provided accurate health history as well as nutrition and exercise status on all pre-
screening materials.  
2. Subjects adhered to pre-testing exercise and dietary guidelines.  
3. Subjects gave maximal effort during exercise time-to-exhaustion testing. 
4. Subjects reported honest answers on all mood and fatigue surveys. 
5. Subjects provided accurate dietary intake information on the dietary intake log. 
6. Subjects adhered to the supplementation protocol throughout the duration of the study. 
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7. Subjects maintained consistent exercise and nutrition habits throughout the duration of the study.  
Statistical 
1. The population from which the sample was drawn was normally distributed. 
2. Treatment group was randomly assigned. 
3. The variability between groups of sample in the experiment was equal or nearly so. 
Definition of Terms 
Gastrointestinal (GI) Tract – The human organ system responsible for transporting and digesting 
food, absorbing nutrients, and expelling waste. 
Gut Microbiota – The collective populations of commensal bacterial residing in the GI tract. 
Shift-working – Individuals employed on a night shift or rotating day/night shift schedule.  
Visceral adipose tissue – Body fat stored within the abdominal cavity around the vital organs 
Significance of Study 
This study attempted to evaluate the influence probiotic supplementation may have on regional 
adiposity and body composition, as well as measures of fatigue in shift-working females.  Though several 
studies have explored the use of probiotics as a therapy for weight loss and mitigation of metabolic 
syndrome, few studies have looked specifically at potential implications for fat distribution.  Literature 
has also suggested benefits of probiotics on performance and inflammation in endurance athletes. 
However, we are not aware of a study that has looked at the interplay of probiotics and exercise fatigue in 
a non-athletic population.  The current study sought to elucidate potential benefits of probiotics on 
adiposity, metabolic health markers, mood, and fatigue in a shift-working female population.  
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CHAPTER II: REVIEW OF LITERATURE 
Over the past decade, interest in probiotics and the gut microbiota has gained momentum in both 
popular media and the scientific community.  Accumulating evidence has linked gut dysbiosis, the 
disruption of microbial equilibrium in the digestive tract, to a series of other health issues including 
metabolic syndrome, gut permeability, and irritable bowel syndrome (IBS).2  Considering the alarming 
public health threat posed by metabolic-related disorders, associations between compromised 
gastrointestinal (GI) health and excess body weight have gained special attention.1  Probiotics have been 
established as a successful therapy to restore GI homeostasis, benefit body composition, and improve 
immunity.36  By enhancing gut health, probiotics may serve as a safe and economical alternative to 
improving body composition and reducing obesity-related symptoms.  
The typical American lifestyle, which generally includes lack of sleep, chronic exposure to stress, 
and consumption of processed foods, has been blamed for the increasing prevalence of GI disorders.1  
Findings suggest that probiotics may specifically benefit abdominal adiposity, which may serve as a 
stronger indication of metabolic-related morbidity risk than other anthropometric measures.6,7  However, 
evidence in human subjects is much more scarce.  Considering the complex physiological and 
psychological components associated with poor gut and metabolic health, more research exploring the 
potential benefits of probiotics is warranted, especially in a highly susceptible population.  Occupational 
health studies have identified higher rates of GI and metabolic disturbances in female shift workers, 
compared to the general population, likely due to unconventional sleep schedules and stressful work 
environments.37,38  Therefore, the current study investigated the influence of probiotic supplementation on 
body composition and metabolic health in rotating-shift female healthcare workers.  The purpose of the 
current review is to provide an overview of the gut microbiota’s influence on human physiology and 
explore mechanisms through which probiotics may directly benefit metabolic health, as well as improve 
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other pathophysiologies associated with obesity.  The review will then describe the susceptibility of the 
proposed population, which may benefit from probiotic supplementation. 
The Human Gut Microbiota  
 Trillions of microorganisms reside in the human GI tract, forming the bacterial community 
collectively known as the microbiota.39  With functions ranging from the digestion and absorption of 
certain nutrients to the promotion of host immunity, the gut microbiota has a profound influence on 
human physiology.  Turnbaugh and colleagues10 propose the existence of a “core” gut microbiome, 
suggesting a certain level of similarity in the genetic make-up of gut bacteria among healthy adults.  
Conversely, disturbances in the composition and activity of gut bacteria can give rise to serious health 
implications.  Compromised microbial diversity has been associated with insulin resistance, obesity, 
mood disorders, and irritable bowel syndrome.2,29,40  As interest surrounding GI disorders grows, a variety 
of environmental factors have been implicated in the increasing prevalence of symptoms related to gut 
dysbiosis. 
Birth through the first 18 months of life has been shown as a formative period of microbiota 
development.41  A rise in the number of cesarean sections, as well as a shift from breast-feeding to 
formula feeding, have both been associated with reduced microbial diversity.8,41,42  Several meta-analyses 
regarding the protective effects of breastfeeding against childhood obesity attribute increased variety of 
gut bacterial strains as a likely mechanism of cause.43,44  It was initially believed that mammals were born 
with a germ-free gastrointestinal tract, having developed in a supposedly sterile womb during gestation.45  
However, recent evidence suggests the fetal microbiota is colonized with some bacteria in utero.41,45  
Consequently, poor pre- and perinatal nutrition may have a profound impact on infant microbiota, 
predisposing offspring to compromised GI health and perpetuating the incidence of metabolic 
diseases.44,46 
From adolescence on, diet continues to significantly influence the microbial make-up of the GI 
tract.  Characteristics of the contemporary Western diet have been blamed as a major contributor to gut 
dysbiosis.15,47,48  Increased agricultural use of low-dose antibiotic administration to promote the growth of 
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farm animals has been implicated in gut microbiota alterations, with Cho and colleagues49 demonstrating 
altered microbiota composition and increased fat mass in mice following 7 weeks of sub-therapeutic 
antibiotic treatment.  However, the nutrient content and quality of food has been the most explored link 
between diet and gut flora.48  Cani et al.50 revealed a significant shift in the ratio of bacterial phyla 
Firmicutes and Bacteroidetes populating the mouse GI tract following the introduction of a high-sugar, 
high-fat chow.  Microbiota changes have also been observed in human subjects following short-term 
exposure to diets high in fat and refined carbohydrates.51,52  Cross-sectional analyses showed notable 
variation in the microbiomes of European children compared to children from rural Africa, most likely 
due to the latter’s higher intake of fiber-rich foods.53  Plant-based diets also result in gut flora differences, 
evidenced by the study of microbiota in vegetarian and vegan individuals.54  Processed foods containing 
refined carbohydrates and poor-quality fats, in addition to their inherent obesogenic effects, likely 
exacerbate gut dysbiosis and further threaten metabolic health.55 
In addition to diet, lifestyle factors such as lack of sleep and chronic stress are also thought to 
adversely shape the bacterial landscape of the gut, hindering microbial diversity and increasing the 
survival of pathogenic microorganisms.13,30,56  Based on theory that the gut microbiota was effected by 
circadian rhythm, Thaiss et al.56 compared bacterial make-up in fecal samples between control mice and 
mice under disrupted light and dark exposure.  Significant alterations in microbiota composition were 
seen in the group of mice with interrupted sleeping patterns, findings that Thaiss subsequently observed 
in a small group of human subjects following periods of jet lag.56  Stress has also been implicated in gut 
dysbiosis, considering the strong associations between psychological stress and symptoms of GI 
distress.57  Bailey et al.58 observed higher concentrations of inflammatory markers and significant shifts in 
the intestinal bacteria community of mice following exposure to a social disruption stress.  Remarkably, 
mice then treated with antibiotics exhibited altered levels of stress markers, suggesting a bidirectional 
interaction between the microbiota and physiological stress response.58  
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Probiotics 
Origins of Use 
 Probiotics, with word origin literally meaning “for life,” have the potential to alleviate symptoms 
of gut dysbiosis by introducing beneficial bacteria to the GI tract.59  In addition to isolated capsule or 
powdered probiotics, fermented products or foods prepared with bacterial cultures such as yogurt, kefir, 
kimchi, and sauerkraut also yield characteristics of probiotics.  According to a joint consensus of Food 
and Agricultural Organization and the World Health Organization experts, probiotics are defined as “live 
microorganisms which when administered in adequate amounts confer a health benefit on the host.”5  
Though most probiotic research has occurred in the past decade, the concept of probiotics has existed in 
many civilizations for thousands of years.  Evidence suggests that culinary traditions across the globe 
embraced fermented foods for their therapeutic properties long before discovery of the microbes 
responsible.60  Today, the lifestyle and dietary factors propelling gut dysbiosis have prompted a mounting 
interest in GI therapies.  Probiotic-containing foods and supplements now make up a global industry 
worth billions of dollars and continue to draw attention as a treatment for a host of maladies ranging from 
insulin resistance to IBS.61–63   
Recently, probiotics have piqued clinical and research interest as a promising aid to weight loss 
and metabolic syndrome through concomitant improvements in intestinal health.  In a study evaluating 10 
weeks of probiotic supplementation in diet-induced obese mice, Park et al.64 reported reduced fat 
accumulation, as well as lower plasma insulin and leptin concentrations in mice receiving Lactobacillus 
curvatus HY7601 and Lactobacillus plantarum KY1032, compared to the placebo group.  Further gene 
analysis of the mice adipose tissue revealed transcriptional down-regulation of pro-inflammatory markers 
(TNFα, IL6, IL1β and MCP1).  Miyoshi et al.7 documented similar findings in mice following a period of 
Lactobacillus gasseri SBT2055 supplementation.  The Lactobacillus gasseri SBT2055 strain was also 
evaluated in humans by Kadooka and colleagues,6 who reported significant reductions in abdominal fat 
mass in 87 overweight men and women.  Many of the studies in recent literature, both murine and human, 
also observed that probiotics tended to specifically benefit abdominal adiposity relative to overall 
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reductions in fat mass.7,65,66  Though more research is needed to elucidate the physiological pathways 
through which probiotics act, existing literature points to several potential mechanisms of action. 
Influence on Energy Metabolism 
 The GI tract is highly involved in both energy uptake through digestion and absorption, as well as 
energy loss in the feces and urine.11  Since a seminal study by Turnbaugh and associates10 demonstrated 
notable variations in the microbiota of lean versus obese twins, it has been theorized that bacterial strains 
differ in their ability to break down and utilize substrates in the human gut.  In one of the many murine-
model studies by Backhed et.al,14 germ-free mice absorbed significantly fewer monosaccharides in the 
intestinal lumen than conventional mice following 14 days of a western-style diet.  Research by Jumpertz 
and colleagues67 observed a similar phenomenon in lean and obese humans.  Following three consecutive 
days of overfeeding (+1000 kcal/day), bomb calorimetry analysis of fecal samples from lean individuals 
revealed a reduction in energy loss averaging 150 kcal.  Subsequent investigations suggest that bacterial 
phyla dominant in obese phenotypes are more capable of hydrolyzing certain polysaccharides and fatty 
acids, increasing the overall amount of calories extracted from food and stored by the host.2 
Reintroduction of beneficial bacteria through probiotic supplementation may attenuate excess energy 
absorption that leads to weight gain and compromised metabolic health.2,4,61 
In addition to directly impacting nutrient harvest, the gut microbiota also influences the activity 
of certain biochemicals regulating energy utilization and storage.  Backhed et al.15 evaluated the influence 
of an obese-phenotype microbiota on metabolic markers by introducing germ-free mice gut to bacteria 
from obese mice fed “western”-style diets.  The formerly-germ free mice exhibited suppressed levels of 
both phosphorylated AMP-activated protein (AMPK), an enzyme that activates catabolic pathways, and 
fasting-induced adipocyte factor (Fiaf), a lipase-inhibiting protein that affects fat deposition.  Favorable 
alteration of the microbiota with probiotics may normalize AMPK and Fiaf expression to restore 
metabolic homeostasis and mitigate excess fat storage.  Disturbances in gut bacteria may interfere with 
insulin signaling, which also plays a role in fat deposition and glucose regulation.2,68  A cross-sectional 
analysis noted significant deviations in the microbiota composition of insulin-resistant versus normal 
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European women, and successfully predicted glucose intolerance based on fecal bacterial analysis.69  
Probiotics have been demonstrated to lower fasting blood glucose and mitigate oxidative stress in both 
type 2 diabetics70 and healthy individuals.16  Murine studies have also suggested probiotics may enhance 
secretion of satiety hormones attenuating overall energy intake.17  However, to date evidence in human 
subjects is scarce.  
Influence on Immunity and Inflammation 
As a major site of entry into the host’s bloodstream, the GI tract functions as a key player in 
immunity.2  A healthy intestinal lining is semi-permeable, highly selective in allowing the absorption of 
vital nutrients and electrolytes, while protecting the host from the entry of pathogens.71,72  However, if the 
integrity of the gut lining is compromised, foreign particles can slip through gaps in the cell wall and 
incite an inflammatory immune response known as “leaky gut syndrome.”40,73 Additionally, excess body 
fat is often accompanied by systemic, low-grade inflammation, which is now acknowledged as a risk 
factor for other obesity-related complications.73   In studies of diet-induced obese mice, Cani et al.74 
observed elevated blood concentrations of bacterial lipopolysaccharide (LPS) that had translocated across 
the gut barrier into circulation.  It confirmed LPS as a driving force of obesity-related inflammatory tone 
by steadily infusing exogenous LPS into normal-weight mice, which subsequently developed insulin 
resistance and whole-body, liver, and adipose tissue weight gain.74  This phenomenon, known as 
“metabolic endotoxemia,” may be mitigated by probiotics to deter symptoms of metabolic disorder.2  
Probiotics benefit gut barrier function by producing peptides that promote the growth of gut epithelial 
cells and enhance tight junction complexes.18,20,23  Probiotics have also been observed to hold a 
competitive advantage over pathogenic microbes for essential nutrients and adhesion sites on the 
intestinal lining, favorably altering the intestinal ecosystem for further proliferation of beneficial 
bacteria.18,19  
Lampretch et al.26 evaluated markers of inflammation and intestinal permeability in 23 
endurance-trained males following 90 minutes of strenuous exercise, then randomly assigned 12 weeks of 
probiotic or placebo supplementation.   Significant reductions in Zonulin, a protein indicating 
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compromised tight junction structure, were observed in the probiotic group. A decrease in TNF-α and 
carbonyl protein was also cited, suggesting improved intestinal integrity, as well as the potential for 
probiotics to mitigate inflammation associated with heavy exercise training.  Shing et al.40 evaluated the 
effects of 4 weeks of probiotic supplementation on performance of 10 male runners in the heat.  
Significant improvements in run time-to-exhaustion were observed in the probiotic group, as well as 
small reductions in markers of intestinal permeability. A small body of literature suggests chronic 
probiotic supplementation may also have an ergogenic effect through improved energy signaling and 
mitigation of muscle wasting.75,76  Probiotics may benefit inflammation related to strenuous activity and 
alleviate symptoms of fatigue.   
Influence on the Brain 
 Symptoms of GI distress often accompany mood disorders including chronic fatigue, anxiety, and 
depression.29  A fundamental link exists between one’s mental and digestive health, apparent in increased 
nausea and symptomatic IBS during times of emotional stress.57   Intestinal bacteria has recently been 
suggested as a critical third party in the gastrointestinal and neural connection, leading to the concept of a 
“microbiota-gut-brain axis.”27  While a disrupted gut microbiota may increase mental health risk, 
probiotics may favorably modulate gut-brain signaling pathways to alleviate symptoms of disordered 
mood.   Certain bacterial strains secrete a variety of neurotransmitters integral to mood and cognitive 
function, including gammaaminobutyric acid (GABA), serotonin, and dopamine.77  Administration of 
single-strain probiotic L. rhamnosis for 28 days increased GABA production in mice, resulting in reduced 
anxiety and depressive behaviors following a forced swimming task.30   Correlational evidence suggests 
the heightened immuno-inflammatory response associated with intestinal permeability also contributes to 
mood disorders, though exact mechanisms are yet to be elucidated.78  Tillisch et al.79 found that 
consumption of a probiotic drink for four weeks altered human brain activity in regions responsible for 
sensory and emotional processing.  Steenberger and colleagues28 evaluated the effects of a multi-strain 
probiotic in healthy adults on cognitive reactivity to sad mood, a known precursor to major depressive 
disorder.  
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improvements in mood based on the Leiden Index of Depression Sensitivity-revised questionnaire, with 
significant reductions in aggressive and ruminative tendencies.  Though more human research is needed 
to elucidate physiological mechanisms at play, current literature supports probiotics as a potential therapy 
for symptoms of impaired mood. 
Populations of Interest 
Risk Among Female Rotating-shift Workers 
While much of the Western population faces an elevated risk of gut disturbances, those employed 
as rotating shift workers may be even more susceptible.  Due to occupational demands, lifestyle factors 
such as unconventional sleeping patterns, physical and emotional stress, and processed food consumption 
may be amplified in this population.3  The prevalence of sleep-related pathologies among shift-workers 
has been classified as “Shift Work Disorder,” characterized by irritability, depression, and insomnia 
despite chronic fatigue.80  Lack of sleep is a known metabolic stressor, with Chaput et al.81 observing a 
significant increase in abdominal adiposity across a six-year period among those averaging less than six 
hours of sleep per night.  Disruptions in circadian rhythm may also contribute to gut dysbiosis,56 a 
phenomenon supported by strong correlations between shift-working and rates of GI disorders.31  Long 
shifts with limited access to nutritious food and adequate hydration, may contribute to poor quality diet 
that further exacerbates symptoms of metabolic and GI distress.  
Compromised health has been observed more in female shift-workers than their male 
counterparts.32  Nursing remains a prevalent field employing a shiftwork model, with women comprising 
more than 90% of nursing professionals.33  Higher relative rates of metabolic disorder are found among 
nursing professionals, a trend with serious implications considering the critical role of nurses in the 
healthcare system.34  Analysis of Canada’s National Survey of the Work and Health of Nurses revealed 
significantly higher BMIs among night- and mixed-shift female nurses compared to those with a more 
conventional schedule.82  Increased rates of functional bowel disorder, anxiety, and sleep disturbances 
have also been observed in rotating-shift nurses, relative to daytime nurses.35  Despite the potential of 
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probiotics to treat pathologies associated with shift-work, we are only aware of one probiotic intervention  
involving a shift-working population.  Tubelius et al.83 reported significantly fewer sick days taken by 
employees during 11 weeks of probiotic supplementation compared to a placebo control group, however 
no other study outcome was explored and subjects were predominantly male.  
Conclusion 
 Probiotics have been demonstrated as a promising remedy for gut dysbiosis, resulting in a variety 
of potential health benefits.4,25,84  The evolution of the modern eating patterns, including industrialized 
agricultural practices, processed food production, and decreased fiber intake, may adversely effect 
colonies of beneficial bacteria that reside in the human gut.51  Additionally, poor sleeping habits and 
chronic stress may further contribute to the growing prevalence of GI disorders.56,85  The occupational 
demands of the nursing profession may put rotating-shift nursing staff at even greater risk for gut 
dysbiosis, further increasing risk for concomitant diseases.  By reintroducing beneficial bacteria to the 
intestinal tract, probiotics have been demonstrated to help reestablish gut homeostasis, thus altering 
metabolic pathways to balance energy harvest and fat storage.2  Probiotics also restore gut barrier 
integrity, alleviating low-grade inflammation that often accompanies disrupted metabolic health, chronic 
fatigue, and exercise intolerance.26,74  Mood-boosting effects have also been documented, indicating 
probiotics may favorably alter gut-brain-microbiota axis signaling pathways to improve psychological 
wellbeing.  Reductions in fat mass have been reported following six weeks of probiotic 
supplementation,86 though only a handful of bacterial strains have been evaluated, and studies in human 
subjects are scarce.  More research exploring the benefits of probiotic supplementation on body 
composition and metabolic health is merited, especially in a susceptible population such as female 
rotating-shift nursing staff. 
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CHAPTER III: METHODOLOGY 
Experimental Design 
The study was a randomized, double blind, placebo-controlled experimental design involving a 
six-week period of daily probiotic administration (Figure 1).  Prior to the pre-screening visit, each subject 
was sent a copy of the informed consent and a three-day dietary intake log to be completed prior to visit 1 
to allow time for dietary analysis.  At the first visit, participants completed medical, nutritional, and 
physical activity questionnaires to screen for exclusion criteria (included below). Eligible participants 
were led through a brief familiarization session with the exercise test protocol to reduce learning effect. 
Visit 2 involved a four-compartment body composition assessment, a series of mood and fatigue surveys, 
a 4 mL blood draw, and a treadmill-walking test.  Participants were then randomized into either a 
treatment group for supplementation of 1) a multi-strain probiotic or 2) a placebo containing 
maltodextrin. Following six of weeks of supplementation, participants returned for a third visit involving 
testing assessments identical to visit 2. 
Participants 
 Premenopausal female volunteers between the ages of 21 and 55 years were recruited. 
Participants were employed as shift-workers (i.e. nurses, certified nursing assistants, emergency medical 
services personnel), working for at least 6 months on a rotating day/night or night shift schedule prior to 
study participation.  Previous research has demonstrated a mean fat mass loss between 0.5 and 0.8 kg 
following between 6 and 12 weeks of daily probiotic administration.6,86  For powering our study, we 
assumed that the mean reduction in fat mass would be 0.7 kg in the treatment group. We further assumed 
a standard deviation of 1.2 kg, in close agreement with results that have previously been reported.6  Under 
these assumptions, enrolling 60 subjects would have provided at least 80% power for a repeated measures 
ANOVA (assuming a 0.3 correlation between measurements) at the 0.05 alpha level.  Power calculations 
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were performed using nQuery + nTerim 2.0. When calculated post hoc, power for lean mass using an 
effect size of 0.095, p-value of 0.081, and correlation of 0.9, power was equal to 74%. Post hoc power 
calculations for fat mass, using an effect size of 0.035, p-value of 0.300, and correlation of 0.9 yielded a 
power of 56%.  
All participants were required to be healthy, with no history of cardiovascular disease, renal, 
hepatic or musculoskeletal disorders, and had maintained a stable bodyweight (±3 kg) during the two 
months prior to testing. Participants were excluded if they were currently consuming or had been 
consuming a daily probiotic supplement in the past two months, or if they habitually consumed (>2 
servings/day) fermented, cultured, or probiotic-fortified foods. A three-day diet log was completed and 
analyzed (Food Processor; ESHA Research, Salem, OR) upon enrollment to assess participants’ baseline 
nutrition.  Participants were encouraged to maintain normal dietary and exercise habits throughout the 
course of the study, filling out a 24-hour diet log at 3 weeks (midway) and 6 weeks (final) into the 
intervention to monitor any major changes in energy intake.  
Preliminary Testing 
Body Composition 
Fat mass (FM), percent body fat (%fat), and lean mass (LM) were calculated using a four-
compartment (4C) body composition model according to Wang et al. 87 [Equation 1], where BV is total 
body volume, TBW is total body water, Mo is total body bone mineral density, and BM is body mass 
measured in kilograms. Test-retest reliability for a 4C model from our lab in a similar population is as 
follows:  Fat mass intraclass correlation coefficient (ICC)=0.994, standard error of measure (SEM)=0.830 
kg, and minimum difference (MD)=2.30 kg; %fat ICC=0.988, SEM=0.868%, MD=2.40%, and LM 
ICC=0.996, SEM=0.842 kg, MD=2.33 kg. 
Equation 1: FM (kg) = 2.748 (BV) – 0.699(TBW) + 1.129(Mo) – 2.051(BM) 
  %fat = (FM/BM) × 100 
  LM (kg) = BM – FM  
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Body volume was calculated using dual energy x-ray absorptiometry (DEXA; GE Lunar iDXA, 
GE Medical Systems Ultrasound & Primary Care Diagnostics, Madison, WI, USA) as previously 
described by Wilson et al.88 and Smith-Ryan et al.89 [Equation 2]. 
Equation 2: BV (L) = (FM)/0.88 + (LM)/1.05 + (BMC)/4.85 + 0.01  
Total bone mineral content (BMC) was estimated using DEXA in order to calculate Mo [Mo = 
BMC (kg) × 1.0436].  Wearing athletic-type clothing free of all metal, participants were centered on the 
DEXA table in a supine position and instructed to lie still for the duration of the scan (7-13 min).  
Regions of interest were created by the same technician. 
Total body water was estimated using multi-frequency bioelectrical impedance spectroscopy 
(BIS; SFB7, ImpediMed, Queensland, Australia).  Subjects were asked to lie supine, with approximately 
a 30° separation between the arms and torso, for a minimum of five minutes before measurements were 
taken.  Leads were connected to four single-tab electrodes placed on the subject’s right wrist and hand, 
and right ankle and foot, with 5 cm between each respective pair of electrodes. The average of two 
measurements was recorded as TBW. 
Regional fat distribution  
Dual-energy X-ray absorptiometry (DEXA; GE Lunar iDXA, GE Medical Systems Ultrasound & 
Primary Care Diagnostics, Madison, WI, USA) was used to estimate visceral adipose tissue mass 
(VATDEXA; kg).  From a total body scan, VATDEXA was estimated from the device software’s (enCORE 
Software Version 16) automatically selected android region-of-interest. The region is set to capture 
abdominal fat spanning from the top of the iliac crest to 20% of the distance between the top of the iliac 
crest and the base of the skull.90  
Visceral adipose tissue thickness (VATUS; cm) was also assessed using brightness-mode (B-
mode) ultrasound (GE LOGIQ-e, Software version R8.0.7, GE Healthcare, WI, USA) with standardized 
settings (Frequency: 4.0 MHz, Gain: 45).  A wide-band convex array ultrasound transducer (GE: C1-5 
RS) was used to capture a still image of the abdomen approximately 5 cm proximal to the umbilicus. The 
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perpendicular distance between the interior border of the rectus abdominis and the posterior wall of the 
aorta was quantified as VATUS.91 
A retractable measuring tape was used to measure waist circumference at the narrowest point 
between the lower ribs and iliac crest, and hip circumference at the largest girth of the hips. The average 
of two measurements were used to calculate waist-to-hip ratio (W:H).  
Exercise to Time-to-Exhaustion 
 To evaluate exercise tolerance, an exercise time-to-exhaustion test on a treadmill was completed 
in accordance with recommendations in the NSCA's Guide to Tests and Assessments.92 According to a 
modified version of the Ebbeling single-stage submaximal treadmill protocol,93 subjects completed one 
minute of walking at 3.4 mph on a treadmill set to 0% grade.  During minutes 2 through 4, speed was 
increased by 0.1 mph every 30 seconds until the subject’s heart rate fell within 5 beats of 60% target heart 
rate (THR), calculated using the Karvonen equation [THR = ((HRmax – HRrest) × %intensity) + HRmax], 
with maximal heart rate (HRmax) defined as 220 - age.  After the fourth minute, the speed was no longer 
adjusted and the incline was increased to 5% grade for another 4 minutes.  Heart rate was recorded every 
30 seconds and ratings of perceived exertion (RPE) were recorded every minute, with no verbal 
encouragement given. Time-to-exhaustion was recorded.  Treadmill speed and grade adjustment was 
duplicated exactly at the return visit. 
Metabolic Biomarkers  
 Prior to the exercise test, a 4mL blood sample was collected from the antecubital region of the 
arm into a sodium heparin tube (BD Vacutainer®). A 40µL subsample was immediately analyzed (within 
5 minutes) for whole-blood total cholesterol (TC), high-density lipoproteins (HDL), and glucose (GLUC) 
using a Cholestech LDX analyzer (Alere Inc., San Diego, CA, USA).  
Questionnaires  
 Participants completed mood and fatigue questionnaires at pre- and post-intervention visits.  The 
Hospital Anxiety and Depression Scale (HADS) is a self-assessment found to be a reliable tool for 
gauging emotional quality of life in both medical practice and community settings.94,95  The HADS 
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consists of 14 questions (7 for anxiety, 7 for depression) answered by circling one of four statements that 
correspond to numbers 0 (normal) through 3 (severe) that allow for Likert-type scoring.  The Chalder 
Fatigue survey (CFQ) is an 11-item, self-completed questionnaire designed to assess both physical (items 
1-7) and mental (items 8-11) fatigue.  The CFQ has been validated in occupational research for a variety 
of populations.96  Each question on the CFQ is answered on a 4-point Likert-type scale ranging from 0 
(asymptomatic) to 3 (most symptomatic), allowing for means and measures of dispersion to be calculated.  
Supplementation 
 Participants were randomly assigned, using Random Allocation Software (Ishran, India) to either 
an experimental probiotic/prebiotic (n=15) or placebo (n=18) group. All participants received 90 opaque 
sachets, one pair for each day of the intervention period plus 3 extra days.  Experimental group probiotic 
sachets contained 4g of freeze-dried powder of the multi-strain probiotic mixture Ecologic®Barrier 
(2.5 × 109 CFU/g; Winclove probiotics, The Netherlands). The probiotic supplement contained the 
following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus 
acidophilus W37, Lactobacillus brevis W63, L.casei W56, Lactobacillus salivarius W24, and 
Lactococcus lactis (W19 and W58), as well as a carrier matrix of maize starch and maltodextrin. The 
prebiotic sachet contained 10g of resistant maize starch (W117).  In the placebo intervention, the sachets 
contained 4g and 10g, respectively, of the carrier matrix (maize starch and maltodextrin), making it 
indistinguishable from the experimental sachets in color, taste, and smell.  Ecologic® probiotics have 
been utilized in previous studies investigating topics relevant to the current study.(insert citations?)  
Participants were instructed to dissolve the powder in 250 mL of water and consume prior to the first 
meal of the day. Participants were asked to keep track of any days missed to monitor compliance.  
Statistical Analysis  
A series of one-way analyses of variance (ANOVA) were used to evaluate baseline differences 
between groups for all outcomes, as well as dietary intake.  For all measures of body composition, 
regional fat distribution, metabolic blood markers, and exercise time-to-exhaustion, a series of 2 × 2 
mixed-model ANOVAs were used, with time (pre- and post-intervention) as the within-subjects factor 
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and treatment (probiotics or placebo) as the between-subjects factor.  Mean scores for each questionnaire 
were calculated and analyzed using a mixed-model ANOVA (time × treatment).  When baseline values 
were significantly different between groups, a one-way analysis of covariance (ANCOVA) was 
performed with baseline values as the covariate. Additionally, 95% confidence intervals (Mean ±  SE 
×1.96) were constructed around pre-post change scores for all outcomes. If the 95% confidence interval 
did not include zero, the change was considered significant (p<0.05).  All analyses were performed using 
SPSS software (Version 20.0; IBM, Somers, NY, USA), with the alpha level set a priori at α = 0.05. 
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CHAPTER IV: MANUSCRIPT 
Potential Influence of a Multi-strain Probiotic on Body Composition and Health in Shift-working Females 
Introduction 
Characteristics of a Western lifestyle, which generally includes lack of sleep, chronic exposure to 
stress, and consumption of processed foods, have been blamed for the increasing prevalence of gut 
dysbiosis, the disruption of microbial equilibrium in the digestive tract.1  Evidence linking disrupted gut 
microbiota to a series of health problems has sparked a growing interest in functional foods and 
supplements containing probiotics and prebiotics.  Recent studies have demonstrated potential benefits of 
probiotics on body composition, accompanying markers of metabolic health, and exercise performance. 
2,4,97   
As the primary site of digestion and absorption, the human gastrointestinal (GI) tract has a 
primary role in regulating energy uptake and loss.11  The introduction of beneficial bacteria through 
probiotic supplementation may improve body composition through a variety of proposed mechanisms, 
including enhanced satiety cues, 4 altered energy absorption,11 and restoration of gut barrier function to 
reduce inflammation.98  Several studies have demonstrated supplementation with probiotic strains from 
the Lactobacillis and Bifidobacterium genera to significantly improve body composition,6,86,99 while 
others have not observed any beneficial effects.100–102  Some findings suggest that probiotics may 
especially benefit abdominal adiposity, which may serve as a stronger prognostic of metabolic-related risk 
than other anthropometric measures.6,7  Probiotics have been shown to exert other metabolic health 
benefits, improving blood lipid profiles and reducing hyperglycemia in certain populations.103–105  Despite 
some promising benefits, equivocal results across different bacterial strains and various study populations 
leave room for more investigations in humans.      
Probiotics have also been demonstrated as a promising therapy for disorders often indirectly 
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associated with metabolic syndrome, including chronic fatigue, exercise intolerance, anxiety, and 
depression.27,28 Recent literature has proposed a bidirectional interaction between GI bacterial 
composition and the nervous system, deemed the “microbiota-gut-brain axis.”13,29 Significant mental 
health improvements have been observed in as little as four weeks of multi-strain probiotic 
supplementation.28,79  The immune-inflammatory response associated with gut dysbiosis has also been 
correlated with symptoms of psychological and physiological fatigue,13 suggesting probiotics may 
ameliorate tiredness and improve exercise tolerance.26,40   
While much of the Western population faces an elevated risk of gut disturbances, those employed 
as rotating shift-workers may be even more susceptible.  Healthcare is one of the most notable fields 
utilizing the shiftwork model.  Due to occupational demands, lifestyle factors such as unconventional 
sleeping patterns, physical and emotional stress, and processed food consumption, may be amplified in 
this population.3  Lack of sleep is a known metabolic stressor, with Chaput et al.81 observing a significant 
increase in abdominal adiposity across a six-year period among those averaging less than six hours of 
sleep per night.  Disruptions in circadian rhythm may also contribute to gut dysbiosis,56 a phenomenon 
supported by strong correlations between shift-working and rates of GI disorders.31,35  Long shifts with 
limited access to nutritious food and adequate hydration, may contribute to poor quality diet that further 
exacerbates symptoms of metabolic dysfunction and GI distress.  Probiotic supplementation may 
especially benefit the female nursing population, considering probiotic therapies target many overlapping 
contributors to excess adiposity and its comorbidities.  
A significant and complex interrelationship exists between disrupted gut microbiota, excess body 
fat, and the adverse health effects accompanying both. Though much literature points to the potential of 
probiotics to ameliorate metabolic disturbances, human studies evaluating changes in body composition 
are scarce. Furthermore, we are not aware of any probiotic intervention that explores effects on fat 
distribution in shift-working females, who may be at greater risk for gut dysbiosis and its implications for 
metabolic health. Therefore, the aim of the present was to investigate the potential benefits of probiotics 
on body composition and regional fat distribution in a female healthcare workers employed on rotating-
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shift schedule.  Biomarkers of metabolic health, mood, fatigue and exercise performance were also 
assessed as complementary outcomes.   
Methods 
Experimental Design 
The present study was a double blind, randomized, placebo-controlled experiment involving 
female shift-working healthcare employees.  All participants completed medical, nutritional, and physical 
activity questionnaires to screen for exclusion criteria (included below) prior to enrollment.  Following an 
8-hr fast, participants reported for baseline testing including anthropometric assessments, a blood draw, 
mood and fatigue surveys, and an exercise time-to-fatigue test (Figure 1).  Participants were then 
randomly assigned to six weeks daily consumption of either a multi-strain probiotic and prebiotic blend 
(PRO), or maltodextrin placebo (PLA) before returning for an identical post-testing session. A three-day 
diet log was completed and analyzed (Food Processor; ESHA Research, Salem, OR) to assess 
participants’ baseline nutrition.  Participants were encouraged to maintain normal dietary and exercise 
habits throughout the course of the study, completing a 24-hour diet log at 3-weeks (midway) and 6-
weeks (final) into the intervention to monitor any major changes in energy intake.  A brief questionnaire 
assessing symptoms of gastrointestinal health was administered at baseline and post-testing to monitor 
potential adverse side effects of supplementation.  All procedures were approved by the University’s 
Biomedical Institutional Review Board, and written informed consent was obtained from all participants 
prior to testing.   
Participants 
 Premenopausal female volunteers between the ages of 21 and 55 years were recruited (Table 1).  
Participants were employed as shift-workers (nurses, certified nursing assistants, emergency medical 
services personnel, i.e.), working for at least six months on a rotating-day/night or night shift schedule 
prior to study participation.  Occupational and demographic characteristics are presented in Table 2.  All 
participants were required to be healthy, with no history of cardiovascular disease, renal, hepatic or 
musculoskeletal disorders.  Participants were excluded if they had not maintained a stable bodyweight (±3 
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kg) or had been consuming a daily probiotic supplement in the two months prior to baseline testing.  Out 
of 42 initially enrolled, 41 participants completed the baseline testing and were randomized to PRO or 
PLA, with one individual declining further involvement.  Five individuals did not return for post-testing, 
three due to unrelated illness and two for unknown reasons.  Three individuals have not yet returned for 
post-testing.  Therefore, 33 participants were evaluated for final statistical analyses (Figure 2).  
Experimental Protocol 
Body Composition 
Fat mass (FM), percent body fat (%fat), and lean mass (LM) were calculated using a four-
compartment (4C) body composition model according to Wang et al.87 [Equation 1], where BV is total 
body volume, TBW is total body water, Mo is total body bone mineral density, and BM is body mass 
measured in kilograms. Test-retest reliability for a 4C model from our lab in a similar population is as 
follows:  Fat mass intraclass correlation coefficient (ICC)=0.994, standard error of measure (SEM)=0.830 
kg, and minimum difference (MD)=2.30 kg; %fat ICC=0.988, SEM=0.868%, MD=2.40%, and LM 
ICC=0.996, SEM=0.842 kg, MD=2.33 kg. 
Equation 1: FM (kg) = 2.748 (BV) – 0.699(TBW) + 1.129(Mo) – 2.051(BM) 
  %fat = (FM/BM) × 100 
  LM (kg) = BM – FM  
Body volume was calculated using dual energy x-ray absorptiometry (DEXA; GE Lunar iDXA, 
GE Medical Systems Ultrasound & Primary Care Diagnostics, Madison, WI, USA) as previously 
described by Wilson et al.88 and Smith-Ryan et al.89 [Equation 2]. 
Equation 2: BV (L) = (FM)/0.88 + (LM)/1.05 + (BMC)/4.85 + 0.01  
Total bone mineral content (BMC) was estimated using DEXA in order to calculate Mo [Mo = 
BMC (kg) × 1.0436]. Wearing athletic-type clothing free of all metal, participants were centered on the 
DEXA table in a supine position and instructed to lie still for the duration of the scan (7-13 min).  
Regions of interest were created by the same technician. 
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Total body water was estimated using multi-frequency bioelectrical impedance spectroscopy 
(BIS; SFB7, ImpediMed, Queensland, Australia). Subjects were asked to lie supine, with approximately a 
30° separation between the arms and torso, for a minimum of five minutes before measurements were 
taken. Leads were connected to four single-tab electrodes placed on the subject’s right wrist and hand, 
and right ankle and foot, with 5 cm between each respective pair of electrodes. The average of two 
measurements was recorded as TBW. 
Regional Fat Distribution  
Dual-energy X-ray absorptiometry (DEXA; GE Lunar iDXA, GE Medical Systems Ultrasound & 
Primary Care Diagnostics, Madison, WI, USA) was used to estimate visceral adipose tissue mass 
(VATDEXA; kg).  From a total body scan, VATDEXA was estimated from the device software’s (enCORE 
Software Version 16) automatically selected android region-of-interest. The region is set to capture 
abdominal fat spanning from the top of the iliac crest to 20% of the distance between the top of the iliac 
crest and the base of the skull.90  
Visceral adipose tissue thickness (VATUS; cm) was also assessed using brightness-mode (B-
mode) ultrasound (GE LOGIQ-e, Software version R8.0.7, GE Healthcare, WI, USA) with standardized 
settings (Frequency: 4.0 MHz, Gain: 45).  A wide-band convex array ultrasound transducer (GE: C1-5 
RS) was used to capture a still image of the abdomen approximately 5 cm proximal to the umbilicus. The 
perpendicular distance between the interior border of the rectus abdominis and the posterior wall of the 
aorta was quantified as VATUS.91 
A retractable measuring tape was used to measure waist circumference at the narrowest point 
between the lower ribs and iliac crest, and hip circumference at the largest girth of the hips. The average 
of two measurements were used to calculate waist-to-hip ratio (W:H).  
Metabolic Blood Markers  
 Following an 8-hr fast, a 4mL blood sample was collected from the antecubital region of the arm 
into a sodium heparin tube (BD Vacutainer®). A 40µL subsample was immediately analyzed (within 5 
 
 
28 
minutes) for whole-blood total cholesterol (TC), high-density lipoproteins (HDL), and glucose (GLUC) 
using a Cholestech LDX analyzer (Alere Inc., San Diego, CA, USA). 
Mood and Fatigue 
 Participants completed mood and fatigue surveys at pre- and post-intervention visits.  The 
Hospital Anxiety and Depression Scale (HADS) is a self-assessment found to be a reliable tool for 
gauging emotional quality of life in both medical practice and community settings.94,95  The HADS 
consists of 14 questions (7 for anxiety, 7 for depression) answered by circling one of four statements that 
correspond to numbers 0 (normal) through 3 (severe) to allow for Likert-type scoring.  The Chalder 
Fatigue Survey (CFQ) is an 11-item, self-completed questionnaire designed to assess both physical (items 
1-7) and mental (items 8-11) fatigue.  The CFQ has been validated in occupational research for a variety 
of populations.96  Each question on the CFQ is answered on a 4-point Likert-type scale ranging from 0 
(asymptomatic) to 3 (most symptomatic). 
Exercise Time-to-Fatigue  
 To evaluate exercise tolerance, an exercise time-to-fatigue test on a treadmill (Woodway Inc., 
Waukesha, WI, USA) was completed. According to a modified version of the Ebbeling93 single-stage 
submaximal treadmill protocol, participants completed one minute of walking at 3.4 mph on a treadmill 
set to 0% grade.  During minutes 2 through 4, speed was increased by 0.1 mph every 30 seconds until the 
subject’s heart rate fell within 5 beats of 60% target heart rate (THR), calculated using the Karvonen 
equation [THR = ((HRmax – HRrest) × %intensity) + HRrest], with maximal heart rate (HRmax) defined as 
220 - age.  After the fourth minute, the speed was no longer adjusted and the incline was increased to 5% 
grade for another 4 minutes.  Incline was then increased by 2.5% every 3 minutes until participants 
reached volitional fatigue, with no verbal encouragement given.  Time-to-fatigue and final rating of 
perceived exertion (RPE) was recorded.  Estimated maximal oxygen consumption (VO2max) was 
calculated using the average of the steady state HR recorded at minutes 6:30 and 7:30 (HRSS) according to 
Ebbeling et. al.93 [Equation 3].  Treadmill speed and incline adjustment was duplicated at post-testing.  
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Equation 3: Estimated VO2max (ml⋅kg-1⋅min-1) = 15.1+21.8 (speed in mph) - 0.327 (HRSS in 
bpm) - 0.263 (speed × age in years) + 0.00504 (HRSS in bpm × age in years) + 5.98 (gender; 
female = 0, male = 1). 
Supplementation 
 Participants were randomly assigned, using Random Allocation Software (Ishran, India) to either 
an experimental probiotic/prebiotic (n=15) or placebo (n=18) group. All participants received 90 opaque 
sachets, one pair for each day of the intervention period plus 3 extra days.  Experimental group probiotic 
sachets contained 4g of freeze-dried powder of the multi-strain probiotic mixture Ecologic®Barrier 
(2.5 × 109 CFU/g; Winclove probiotics, The Netherlands). The probiotic supplement contained the 
following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus 
acidophilus W37, Lactobacillus brevis W63, L.casei W56, Lactobacillus salivarius W24, and 
Lactococcus lactis (W19 and W58), as well as a carrier matrix of maize starch and maltodextrin. The 
prebiotic sachet contained 10g of resistant maize starch (W117).  In the placebo intervention, the sachets 
contained 4g and 10g, respectively, of the carrier matrix (maize starch and maltodextrin), making it 
indistinguishable from the experimental sachets in color, taste, and smell.  Ecologic® probiotics have 
been utilized in previous studies investigating topics relevant to the current study.26,28  Participants were 
instructed to dissolve the powders in 250 mL of water and consume prior to the first meal of the day.  A 
brief digestive health survey was administered pre- and post-testing to assess potential effects on GI 
symptoms.  Participants were asked to keep track of any days skipped to monitor compliance.   
Dietary Analysis 
Participants completed a three-day diet log at baseline along with two 24-hour diet logs at 3-
weeks (midway) and 6-weeks (final) to assess any potential changes in habitual carbohydrate, fat, protein 
and total caloric intake.   Diet logs were analyzed using Food Processor Software (ESHA Research, 
Salem, OR).  There were no significant differences between time points for intake of carbohydrates 
(p=0.862), fat (p=0.810), protein (p=0.758) or total calories (p=0.856). 
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Statistical Analysis  
A series of one-way analyses of variance (ANOVA) were used to evaluate baseline differences 
between groups for all outcomes, as well as dietary intake.  For all measures of body composition, 
regional fat distribution, metabolic blood markers, survey scores, and exercise fatigue, a series of 2 × 2 
mixed-model ANOVAs were used, with time (pre- and post-intervention) as the within-subjects factor 
and treatment (probiotics or placebo) as the between-subjects factor.  When baseline values were 
significantly different between groups (HADS; CFQ-11; GLU), a one-way analysis of covariance 
(ANCOVA) was performed with baseline values as the covariate.  Additionally, 95% confidence intervals 
[Mean ± Standard Error (SE)×1.96] were constructed around pre-post change scores for all outcomes. If 
the 95% confidence interval did not include zero, the change was considered significant (p<0.05).  All 
analyses were performed using SPSS software (Version 20.0; IBM, Somers, NY, USA), with the alpha 
level set a priori at α = 0.05. 
Results 
There were no significant differences at baseline between groups for any body composition 
outcome (FM, %fat, and LM) or for any measure of regional fat distribution (VATDEXA, VATUS, W:H). 
Baseline TC and HDL were not different between groups, but GLU was significantly higher in PRO at 
baseline (p=0.044). Baseline differences were also observed for mood and fatigue questionnaires 
(p>0.05).  Thus, analyses of covariance were carried out for GLU, HADS-A, HADS-D, and CFQ-11. 
Body Composition 
 For FM, there was no significant time × treatment interaction observed for FM (p=0.300), with no 
main effect for time (p=0.116) or treatment (p=0.716). For %fat, there was no significant interaction 
(p=0.167), and no main effects for time (p=0.180) or treatment (p=0.696).  For LM, there was no 
significant interaction (p=0.081), and no main effect for time (p=0.329) or treatment (p=0.443).  
Analyses of 95% confidence intervals revealed a significant increase in FM for PLA [CI: 0.03–
1.54 kg], as well as trends towards a significant increase in %fat [-0.09–2.80 kg] and decrease in LM [-
2.76– 0.19 kg] for PLA (Table 4, Figure 3).  
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Regional Fat Distribution 
For VATDEXA there was no significant time × treatment interaction (p=0.553), with no main effect 
for time (p=0.698) or treatment (p=0.864).  For VATUS, there was no significant interaction (p=0.780) or 
main effect for treatment (p=0.782), but there was a significant main effect for time (p=0.025), with 
VATUS decreasing from pre to post. For W:H, there was no significant time × treatment interaction, 
(p=0.844), with no main effect for time (p=0.718) or treatment (p=0.568).   
Analysis of 95% confidence intervals did not indicate any significant differences in change scores 
pre to post within either group for any measure of regional fat distribution (Table 4, Figure 4A-B). 
Metabolic Biomarkers 
 For TC, there was no significant time × treatment interaction (p=0.623) or treatment effect 
(p=0.697), though there was a main effect for time (p=0.047) with significant TC increases averaged 
across groups (Table 5).  For HDL, there was no significant interaction (p=0.587), with no main effects 
for time (p=0.920) or treatment (p=0.822). For glucose, an analysis of covariance was performed to 
account for significant baseline variation between groups (p=0.044).  When covaried for baseline values, 
there was no significant difference in changes in GLU (p=0.407).  
Analysis of 95% confidence intervals did not indicate any significant differences in change scores 
pre to post within either group for any metabolic blood markers (Figure 5). 
Mood and Fatigue 
Due to significant group differences as baseline, all survey scores were analyzed using an 
analysis of covariance. When covaried for baseline values, there was no significant difference in changes 
for HADS-A (p=0.621), HADS-D (p=0.506), or CFQ-11 (p=0.773; Table 6). 
Exercise Time-to-Fatigue 
For TTE, there was no significant time × treatment interaction (p=0.769), with no main effects for 
time (p=0.756) or treatment (p=0.700).  For estimated VO2max, there was no significant interaction 
(p=0.869) or main effect for treatment (p=0.370), but there was main effect for time (p=0.004), with 
VO2max increasing from pre to post (Table 7).  
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Compliance, Tolerance, and Palatability 
 Participants reported missing 1.9 ± 1.0 days of supplementation during the intervention period. 
Five participants had minor complaints about the texture and consistency of the supplement, four of 
which belonged to PRO and the other to PLA.  No adverse GI symptoms were reported in either group.  
Participants’ carbohydrate, fat, protein and total caloric intake at the midpoint and return did not 
significantly differ from baseline (p>0.05).   
Discussion 
Recent insight suggests probiotic consumption has the potential to improve metabolic health by 
attenuating obesity and its associated disorders.4,97,106,107  However, the conferred benefits tend to be 
highly variable, with some studies observing no effect for probiotic supplementation on anthropometric 
outcomes.100–102  Of the limited investigations conducted in humans, few have involved healthy females, 
and none to our knowledge have considered the occupational status of the study population. The aim of 
the current investigation explored the potential influence of a multi-strain probiotic on body composition 
and related health markers in female shift-working healthcare employees.  No significant effect for PRO 
was observed on FM, %fat, LM or any measure of regional fat distribution including VATDEXA, VATUS, 
or W:H.  Furthermore, changes in metabolic blood markers, mood survey scores, and exercise fatigue 
outcomes did not significantly differ between PRO and PLA following six weeks of supplementation.   
Prior studies utilizing bacterial strains from the Lactobacillis and Bifidobacterium genera, which 
encompass six of the seven strains utilized in the current PRO, have demonstrated improvements in body 
composition,6,86,99,108 while others have found no beneficial effect.100–102  In the current study, no 
statistically significant alterations in body composition (FM, %fat, LM) were observed in either group.  In 
a study of 43 healthy adults, daily consumption of capsules containing Bifidobacterium Breve B-3 (B. 
Breve; 5 × 1010 cfu) for 12 weeks resulted in a mean FM loss of 0.7 kg, compared to 0.2 kg in the placebo 
control group.  However, the control group also lost LM after 12 weeks, while those supplementing with 
B. Breve gained an average of 0.9 kg LM.  The current study also observed a potential protective effect of 
probiotics on LM.  When evaluating 95% confidence intervals, FM gains were significantly higher from 
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baseline with PLA (Δ0.79 ± 1.63 kg) but not with PRO (Δ0.14 ± 1.20 kg).  In the PLA group, %fat 
trended towards an increase (Δ1.36 ± 3.13%) and LM trended towards a loss (Δ-1.29 ± 3.19 kg).  
Conversely, a modest decrease in %fat (Δ-0.02 ± 1.77%) and increase in LM (Δ0.34 ± 1.55 kg) was 
observed with PRO (Table 4, Figure 3).  Kadooka et al.6 observed a mean FM loss of 0.8 kg in adults 
consuming 200g/day for 12 weeks of fermented milk containing Lactobacillus Gassieri SBT2055 
(LG2055; 5 × 1010 cfu/100 g of milk), compared to a 0.3 kg FM gain with placebo.  Significant reductions 
were also reported in the milk blend for %fat, BMI, waist circumference, and abdominal fat area.  Despite 
belonging to the same genera as the aforementioned studies, PRO from the current study did not contain 
B.Breve or LG2055, suggesting species variation likely contributes to the efficacy of probiotic use.  
Further investigation of varied probiotic strains is warranted to explore potential interaction effects of 
individual bacterial species.  Positive effects on body composition have also been observed in shorter 
invention periods of probiotic supplementation,86,109 which supports the present study’s six-week 
protocol.  In a randomized crossover study design, 28 overweight/obese adults (Average BMI: 31.6 ± 0.7 
kg·m-2) consumed three different yogurts (containing Lactobacillus amylovorus and Lactobacillus 
fermentum) for six weeks, resulting in a 4% and 3% reduction in fat mass respectively, compared to 1% 
reduction with the placebo control yogurt.86  Four weeks of multi-strain synbiotic (multi-stain probiotic 
plus fructoligosaccharides) supplementation in obese children (BMI: >30 kg·m-2) resulted in greater fat 
losses than lifestyle modification alone.109  However, both studies involved participants with higher 
baseline BMIs than participants in the present study (BMI: 24.7 ± 3.8 kg·m-2).  A longer intervention 
period may be necessary to reveal body composition alterations in more normal-weight individuals, 
considering the margin of improvement would be smaller. 
Beyond global body composition alterations, probiotics appear to especially target regional losses 
in visceral adipose tissue (VAT).25  As a pro-inflammatory endocrine organ, visceral adiposity correlates 
closely with cardiometabolic disease and may indicate compromised health even among individuals 
without other metabolic risk factors.110 Takashi et al.99 administered 100g of fermented milk containing 
either Bifidobacterium lactis GCL2505 (~8 × 1010 cfu/100g) or a placebo control to 137 healthy adults for 
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12 weeks.  Along with traditional anthropometrics, abdominal fat distribution was assessed using 
computed tomography (CT); a significant effect was observed in the probiotic group on visceral fat area 
(Mean Δ -5.1 cm2), but not on subcutaneous fat area, total fat area, body weight, BMI or W:H ratio.  
Kadooka et al.108 reported that both a 106 and 107 cfu dosage of LG2055 resulted in similar visceral fat 
area losses (8.2 cm2 and 8.5 cm2 respectively), while no significant changes occurred in the placebo 
group.  In the current study, the PLA group gained visceral fat mass (VATDEXA; Δ0.016 ± 0.11 kg), while 
PRO demonstrated a modest decrease (Δ-0.003 ± 0.07 kg), though neither change reached significance 
(Table 4, Figure 4A).  The current investigation’s use of iDXA enCORE software is a novel approach to 
VAT estimation in studies exploring probiotics and adiposity.  Therefore, differences in the modality of 
assessment limit direct comparisons of present results to the VAT changes observed in previous literature, 
which utilized CT-derived cross-sectional area.6,99,108 Based on an assumed adipose tissue density of 0.905 
g/mL,111 a 0.016 kg VAT reduction demonstrated in the current study, would speculatively translate into 
an adipose volume loss of approximately 17 cm3.  Although baseline VAT values were normally 
distributed, they were also highly variable among participants. One individual exhibited 1.893 kg of 
VAT, while three others possessed undetectable amounts (0.00 kg), leaving them no margin for VAT 
reductions regardless of intervention.  Such variability may have contributed to the lack of significant 
effects. For VATUS, both groups demonstrated reductions in visceral fat thickness, though PRO had a 
greater mean decrease than PLA (Δ-0.196 ± 0.53 cm vs. Δ-0.250 ± 0.56 cm; Figure 4B).  
Ultrasonography has been validated with CT as a method of VAT assessment, however the technique 
introduces more potential for technician error than DEXA, potentially explaining the inconsistency in 
VAT outcomes between the two methods.112  Differences in study population may have also hindered the 
ability to make direct comparisons of changes in regional fat distribution.  
Previous literature suggests probiotics have the potential to improve biomarkers of metabolic 
health, although evidence has not been conclusive across a variety of strains and study populations.  The 
present study failed to show any significant differences in blood marker changes (TC, HDL, or GLU) 
between PRO and PLA.  Minami et al.113 also reported no effect of B. breve on blood lipids or fasting 
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blood glucose levels despite significant benefits to body composition.  Conversely, Moroti et al.104 
observed significant increases in HDL and reductions in fasting glucose after 30 days daily consumption 
of a synbiotic shake (Lactobacillus acidophilus, Bifidobacterium bifidum + fructooligosaccharides). 
However, inclusion required participants to have total cholesterol ≥200mg/dL and fasted blood glucose 
≥110 mg/dL. In contrast, the majority of participants in the current study exhibited normal metabolic 
blood parameters at baseline (Table 8), with three individuals possessing at-risk TC, three individuals 
with at-risk HDL, and four individuals with prediabetic concentrations of GLU.  Only one individual 
expressed multiple metabolic biomarker risk factors (subnormal HDL and elevated GLU).  These results 
are similar to that of Greaney et al.,114 who reported two months daily supplementation of synbiotic 
capsules (Lactobacillus acidophilus, Bifidobacterium longum + fructooligosaccharides) had no effect on 
any blood lipids in normocholesterolemic men and women.  Though evidence from prior studies suggests 
several cholesterol-lowering and hypoglycemic mechanisms with the Lactobacillus and Bifidobacterium 
species found in the current PRO,115 it is possible that beneficial effects are more evident in individuals 
already possessing elevated metabolic blood parameters.   
Investigations linking gut dysbiosis to mental and behavioral health has prompted scientists to 
evaluate the effect of probiotics as potential aids to mood and fatigue disorders.29,116–118  Following four 
weeks of supplementing with the same PRO formula used in the current study, Steenberger et al.28 
observed significant reductions in depressive tendencies as assessed by the Leiden Index of Depression 
Sensitivity,119 but no significant changes were seen in scores on the Beck Depression Index or Beck 
Anxiety Index.  In the current study, reductions in anxiety (HADS-A, Δ-1.6 vs Δ-0.6) and fatigue (CFQ-
11, Δ-3.7 vs Δ-1.6) were greater in PRO than PLA, respectively.  Depression scores decreased modestly 
with PRO (HADS-D, Δ-0.7) while a slight increase was observed in PLA (Δ+0.1). Although none of the 
changes reached statistical significance, some appear to be clinically relevant based on each 
questionnaire’s score classifications.  Baseline scores among PRO were considered above-normal for 
HADS-A (>7 pts)94 and CFQ (>14.2 pts),120 compared to normal baseline scores in PLA.  Following PRO 
supplementation in the current study, all mood and fatigue scores fell into normal ranges (Table 6).  These 
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results suggest a potential beneficial effect on anxiety and mental fatigue in a shift-working population 
combatting the stress and schedule demands of healthcare field.  
As a known contributor to intestinal permeability, a disrupted microbiota has been implicated as a 
source of inflammation that may exacerbate performance and recovery from physical activity.26,40  
Lamprecht et al.26 demonstrated reductions in markers of intestinal permeability and inflammation 
following strenuous exercise in cyclists supplementing with a probiotic for 14 weeks.  Shing et al.40 
observed greater time to fatigue in a heat-stressed running task following four weeks probiotic 
supplementation.  The current study demonstrated no significant effect of PRO on estimated VO2max or 
TTE.  It is possible that weekly schedule variability among individual participants confounded more 
pronounced effects on exercise performance. 
  The present study was the first of its kind to explore the influence of a multi-strain probiotic on 
body composition and other metabolic-related outcomes in a female shift-working population.  Unique 
occupational risk factors faced by female rotating- and night shift healthcare employees include disrupted 
and variable sleep schedules, stressful work environment, and limited access to healthy foods. Though 
previous cross-sectional analyses have observed greater incidence of GI and metabolic disturbances in 
female shift-workers,38,121 the majority of participants in the present study were non-obese and had normal 
metabolic biomarker values.  Selection bias may have influenced the current study sample, with more 
health-conscious individuals choosing to participate, and should be considered a limitation.  Moreover, 
individual work schedule rotations were not accounted for when scheduling pre-and post-testing visits, 
meaning fluctuations in job-related stress and fatigue may have influenced study outcomes.  Future 
investigations may consider tracking the specific number and type (day or night) of shifts worked 
throughout the intervention period, and attempt to maintain congruency in the days prior to all testing 
sessions. Results of this study may shape future occupational health investigations involving probiotics 
and body composition, especially in susceptible populations. 
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CHAPTER V: CONCLUSION 
Results of the present study demonstrate a potential protective effect of PRO on body 
composition compared to PLA, though differences between treatments did not reach statistical 
significance.  Probiotics did not significantly influence VAT, but modest decreases with PRO suggest 
potential for visceral fat reductions, especially in populations with greater VAT accumulation.  Changes 
in biomarkers of metabolic health, including TC, HDL and GLU, were not different between treatments.   
Although statistically non-significant, improvements in HADS and CFQ-11 scores with PRO may be 
clinically relevant to support future probiotic treatments to aid mood and fatigue.  Probiotics did not 
improve exercise fatigue or estimated VO2max compared to PLA.  Occupational factors and schedule 
demands likely had a strong influence on study outcomes, but this is the first study to explore the effects 
of probiotic supplementation in shift-working females.  Future research should consider the effects of 
various bacterial strains, and seek to account for individual schedule rotations when establishing the 
length and timing of the intervention period. Results of this study may shape future occupational health 
investigations involving probiotics and body composition, especially in susceptible populations.  
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TABLES 
Table 1.  Participant characteristics by treatment (Mean ± SD) 
 Active (n=15) Control (n=18) 
Age (years) 30.5 ± 7.7 30.2 ± 10.0 
Weight (kg) 68.5 ± 9.5 68.2 ± 12.7 
Height (cm) 165.2 ± 5.2 164.9 ± 8.0 
BMI (kg·m-2) 25.1 ± 3.4 24.3 ± 4.2 
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Table 2.  Occupational and demographic information 
  n=33 
Race   
Caucasian  31 
African American  2 
Age (years)  
21-29 19 
30-39 7 
40-49 5 
50-55 2 
Occupation  
Registered Nurses 24 
Nursing Assistants 5 
Emergency Medical Services Personnel 4 
Schedule 	Rotating day/night-shift 31 
Exclusively night-shift  2 
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Table 3. Dietary intake across intervention period for both groups collapsed	
  Calories PRO (g) %PRO CHO (g) %CHO FAT (g) %FAT 
Baseline 1752.7 70.5 16.1 197.3 47.0 71.9 36.9 
Midway 1800.2 66.2 14.7 205.7 48.0 74.6 37.3 
Final 1752.0 70.1 16.0 199.2 45.1 75.8 38.9 
Protein = PRO; Carbohydrates = CHO.  
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Table 4. Effects of supplementation on anthropometric outcomes (Mean ± SD) 
 Active (n=15)  Control (n=18)  
 pre post pre post 
Body Composition     
Fat Mass (kg) 22.8 ± 6.2 23.3 ± 5.8 21.5 ± 9.1 23.4 ± 10.7 
Body fat %  33.1 ± 5.7 33.7 ± 5.6 31.5 ± 8.2 33.2 ± 9.6 
Lean Mass (kg) 45.4 ± 6.8 45.5 ± 6.3 44.6 ± 6.1 44.4 ± 4.6 
Regional Fat Distribution     
VATUS (cm) 3.85 ± 1.15 3.60 ± 0.96 3.72 ± 1.11 3.52 ± 0.96 
VATDEXA (kg) 0.292 ± 0.23 0.288 ± 0.22 0.305 ± 0.46 0.321 ± 0.49 
W:H  0.74 ± 0.04 0.74 ± 0.04 0.73 ± 0.06 0.73 ± 0.06 
VATDEXA = Visceral adipose tissue mass; VATUS = Visceral adipose tissue thickness; W:H=Waist-to-hip 
ratio 
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Table 5. Effects of supplementation on metabolic blood markers (Mean ± SD) 
 Active (n=12) Control (n=18) 
 pre post pre post 
TC (mg/dL) 165 ± 18 174 ± 25 170 ± 27 175 ± 25 
HDL (mg/dL) 58 ± 13 59 ± 15 61 ± 14 59 ± 17 
GLUC (mg/dL) 94 ± 8 94 ± 8 89 ± 6 89 ± 7 
TC= Total Cholesterol; HDL=High Density Lipoproteins; GLU=Glucose   
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Table 6. Mood and fatigue questionnaire scores (Mean ± SD) 
 Active (n=15) Control (n=18) 
 pre post pre post 
HADS-A 7.4 ± 4.1 5.8 ± 3.3 5.4 ± 2.5 4.8 ± 2.5 
HADS-D 3.3 ± 2.5 2.6 ± 2.4 1.4 ± 1.3 1.5 ± 1.3 
CFQ-11 16.1 ± 4.1 12.4 ± 4.0 13.0 ± 4.0 11.4 ± 2.9 
HADS=Hospital Anxiety and Depression Scale (A=Anxiety, D=Depression); CFQ-11=Chalder Fatigue 
Survey 
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Table 7.  Exercise performance (Mean ± SD) 
	 	 	 	  Active (n=15)   Control (n=18)   
  pre post  Δ pre post  Δ 
TTE (min) 17.9 ± 3.2 17.2 ± 4.1 -0.28 17.6 ± 5.1 17.1 ± 4.6 -0.01 
estVO2max 
(mL/kg/min) 43.8 ± 6.6 45.0 ± 5.5 1.15 45.8 ± 6.7 47.0 ± 6.4 1.28 
TTE=Time-to-exhaustion; estVO2max=estimated maximal oxygen consumption; Δ=change 
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Table 8. Risk stratification of baseline metabolic blood markers 
 Normative Ranges n=30 
Total Cholesterol  
Low (<100 mg/dL) 0 
Normal (100-199 mg/dL) 27 
High (≥200 mg/dL) 3 
HDL 
Healthy (≥60 mg/dL) 15 
Average (40 - 59 mg/dL) 12 
Low (<40 mg/dL) 3 
Fasting Glucose  
Normal (<100 mg/dL) 26 
Prediabetic (100 - 125  mg/dL) 4 
Diabetic (>125 mg/dL) 0 
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FIGURES 
 
Figure 1. Experimental protocol schematic  
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In-Person 
Enrollment Visit 
(n=43) 
Tested at Baseline  
(n=41) 
Excluded (n=1) 
• Did not meet multiple inclusion criteria (n=1) 
Enrolled 
(n=42) 
Excluded (n=73) 
• Currently taking probiotic supplement (n=2) 
• Unable to meet time requirements (n=2)  
• ≥8 lbs weight change in the prior two months (n=1) 
• Not employed on rotating-shift schedule (n=15) 
• Did not meet multiple inclusion criteria (n=22) 
• Did not respond to follow-up contact (n=31) 
 
 Initial Electronic 
Correspondence 
(n=115) 
Excluded (n=1) 
• Unable to meet time requirements (n=1) 
Completed and 
analyzed 
(n=33) 
Excluded (n=8) 
• Withdrew due to illness (n=2) 
• Did not provide explanation for withdrawal (n=2) 
• Return appointment delayed due to illness (n=2) 
• Return appointment scheduled (n=2)  
Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram of participant flow (1) Figure 2. CONSORT (C nsoli ated Standards of Reporting Trials) diagram of participant flow 122 
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Figure 3. Mean changes in body composition outcomes fat mass (FM; kg), percent body fat (%fat), and 
lean mass (LM; kg). Error bars represent 95% confidence intervals (Mean ± 1.96 × SE). *indicates 
significant difference (p<0.05) 
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Figure 4A-B. Mean changes in measures of visceral adipose tissue. A) VATDEXA (kg). B) VATUS (cm).  
Error bars represent 95% confidence intervals (Mean ± 1.96 × SE).  
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Figure 5. Mean changes in metabolic blood markers total cholesterol (TC), high density lipoproteins 
(HDL), and glucose (GLU) (mg/dL). Error bars represent 95% confidence intervals (Mean ± 1.96 × SE).  
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